Press release
Synergy Pharmaceuticals Sues Rival Ironwood Pharmaceuticals in Drug Patent Case
NEW YORK - Synergy Pharmaceuticals, Inc. (Nasdaq:SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq:IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie.The lawsuit alleges that after European Patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.
In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.
Synergy's proprietary drug candidate plecanatide is a synnthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract.
Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012.
Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases.
Contact:
Alex Michelini, Synergy Media representative
michelinialex@aol.com
The Promotion Factory
5 E. 19th Street
New York, NY 10003
212-217-9065
www.thepromofact.com
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and disease.
420 Lexington Avenue, Suite 1609
New York, NY 10170
Contact: Alex Michelini, media representative
201-831-0171
michelinialex@aol.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Synergy Pharmaceuticals Sues Rival Ironwood Pharmaceuticals in Drug Patent Case here
News-ID: 203967 • Views: …
More Releases from Synergy Pharmaceuticals, Inc.
How the Cure for Herpes Became Mired in Controversy. The latest chapter in the b …
Over several decades, the Food and Drug Administration (FDA) has gone to great lengths to maintain its longstanding relationship with major pharmaceutical companies, namely by approving numerous medications. (Many of those approvals, for prescription medicines like Isotretinoin, Pemoline, and Propoxyphene, were eventually recalled after causing patient deaths or irreversible damage.) And this dynamic hasn’t been limited to medical treatments. Despite extensive research that shows sugar is the…
More Releases for Patent
Spectral Capital Announces Substantial Patent Milestone; Continues Globally Comp …
Image: https://www.globalnewslines.com/uploads/2025/02/1738774387.jpg
SEATTLE - Feb 5, 2025 - Spectral Capital Corporation (OTCQB: FCCN [https://www.prnewswire.com/news-releases/spectral-capital-announces-substantial-patent-milestone-continues-globally-competitive-quantum-patent-strategy-302368601.html?tc=eml_cleartime#financial-modal]), a deep quantum technology platform company, is pleased to announce the achievement of a second major patent milestone in its plan to become a globally competitive leader in quantum computing patents.
"We are proud to announce that we have filed 104 provisional patent applications in the field of quantum computing. We promised our shareholders we would have these…
iFLY/SkyVenture patent restricted by European Patent Office
Gladbeck, 21 September 2016. In the patent invalidity attack of the German manufacturer of freefall simulators, Indoor Skydiving Germany Group (ISG) against its US competitor iFLY/S Skyventure International (UK) Ltd (iFLY), the European Patent Office ruled in favor of ISG and restricted the relevant parts of iFLY´s European Patent No. EP 2 287 073. iFly may choose to appeal this decision.
ISG, German manufacturer of high performance freefall simulators for professional…
Patent Drafting Program
PATENT DRAFTING PROGRAM AT IIPTA
By Rachana
February 06, 2013
Delhi, Indian Institute of Patent and Trademark Attorney announces the introduction of Patent Drafting Program as one among the many Intellectual Property related programs offered by the company. This program is focussed mainly on providing an in-depth understanding and writing of patent language in an advanced level.
…
American Megatrends Announces US Patent Awards for 2011, Reaches 200 Patent Mile …
NORCROSS, GEORGIA – Continuing its long tradition of excellence in BIOS, remote management and network storage innovations, American Megatrends (AMI) is pleased to announce its latest round of patent awards. AMI has received an impressive total of 51 U.S. patents from December 28, 2010 through December 20, 2011.
Notably, a total of 23 AMI engineers in collaboration across the globe were directly involved in the research and development of the patented…
Intellectual Property Law Departments decrease Patent Staff, yet Patent Efficien …
ipPerformance Group, a leader in benchmarking corporate intellectual property law and management operations announces the release of its 2012 Intellectual Property Law Department study. While there was an increase in innovation activity worldwide throughout 2010 and 2011, companies reported decreased numbers of in-house IP Attorneys and IP Staff. The total IP Staff and Attorneys worldwide is down 18%; with the decrease in staff being compensated for with increased law…
ParkerVision’s Telecom Patent Portfolio Honored Among Patent Board’s Top 30
Wireless technology firm leads telecom sector in three of six categories
JACKSONVILLE, Fla., Jan. 20, 2012 – ParkerVision, Inc. (Nasdaq: PRKR), a developer and marketer of semiconductor technology solutions for wireless applications, again is ranked among The Patent Board’s top 30 strongest patent portfolios in the wireless and telecom industry, including leading the telecom sector with first place rankings in three of six scoring criteria.
The ranking is based on The Patent…
